Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$7.7MCash on Hand
6.6mo Cash Runway
Follow BIVI by emailGet an email when BIVI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BIVI, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Shareholder vote Shareholders at the Nov 10, 2026 annual meeting elected all six director nominees, ratified EisnerAmper LLP as auditor for fiscal 2027, and approved raising the 2019 Omnibus Equity Incentive Plan share reserve from 399,509 to 3,100,000 shares. Form 8-K · SEC filing
Nov 6, 2026 ·
Financing Priced a $4.74 million registered direct offering and concurrent private placement at $1.60 per share, with 2,962,500 common warrants at $1.70 exercisable after six months. Closing expected November 5, 2026, and A.G.P./Alliance Global Partners is the placement agent at a 7.0% fee. Form 8-K · SEC filing · Press release
Nov 6, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Financing Amends the prospectus supplement to cut the at-the-market common stock offering under the sales agreement with A.G.P. to up to $285,000, down from $1,225,000. Shares last traded at $1.34 on November 4, 2026. Form 424B5 · SEC filing
Nov 4, 2026 ·
Financing BioVie amended its September 11, 2026 prospectus supplement to cut its at-the-market common stock sale program with A.G.P. to up to $1,225,000, down from $6,464,341. Shares last traded at $1.73 on November 3, 2026. Form 424B5 · SEC filing
Sep 28, 2026 ·
Shareholder vote BioVie is asking stockholders to vote at a virtual annual meeting on November 10, 2026 on electing six directors, ratifying EisnerAmper LLP as auditor for fiscal 2027, and increasing shares under its 2019 Omnibus Equity Incentive Plan from 399,509 to 3,100,000. Form DEF 14A · SEC filing
Sep 14, 2026 ·
Financing BioVie is offering up to $6,464,341 of Class A common stock through A.G.P. as sales agent, with a 3.0% commission on gross proceeds. The last reported price was $2.07 on September 8, 2026. Form 424B5 · SEC filing
Sep 14, 2026 ·
Financing BioVie entered a sales agreement with A.G.P./Alliance Global Partners to sell up to $6,464,341 of Class A common stock through an at-the-market offering. The company pays a 3.0% commission and will use proceeds for general corporate purposes. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Aug 2026 · Phase 2 · Results Expected · NE3107 in Adults With Neurological Symptoms of Long COVID Registry primary completion date, not a results date
May 2026 · Phase 2 · Results Expected · A Study of NE3107 in Early Parkinson's Registry primary completion date, not a results date
Sep 2023 · Phase 3 · Results Expected · A Phase 3 Study of NE3107 in Probable Alzheimer's Disease Registry primary completion date, not a results date
Nov 2022 · Phase 1/2 · Results Expected · NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa Registry primary completion date, not a results date
Apr 2019 · Phase 2 · Results Expected · Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not BIVI's own candidates): Terlipressin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
BIVI holds $7.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.5M/quarter from operations,
an estimated runway of 6.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:74 · High
Cash runway 7 months +30
ATM program on file since Nov 2026 +15
Shelf registration (S-3, Jun 2026) +10
Going-concern doubt in the latest 10-Q +15These circumstances raise substantial doubt on the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count +42% in a year +14
Raised after last reported balance sheet (Nov 2026) -10
Share count 10,724,724 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BIVI picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BIVI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.